Clearant Sterilization Service Selected by Tissue Distributor Representing Approximately 10% of the U.S. Market.

LOS ANGELES -- Clearant, Inc. (OTCBB: CLRI), the developer of the patent-protected CLEARANT PROCESS(R), announced today that a distributor accounting for approximately 10% of the $1 billion U.S. tissue market has signed an agreement to adopt the CLEARANT PROCESS.

Community Tissue Services (CTS), with ten locations throughout the country in addition to its headquarters in Dayton, Ohio, is one of the larger non-profit tissue banks in the United States. Investment firm Piper Jaffray has estimated the 2005 U.S. tissue market to be approximately $1 billion and Emerging Growth Equities has forecasted a 15 - 20% growth rate of the market.

This new agreement allows CTS to use the Clearant Sterilization Service (CSS) for a variety of human-sourced soft-tissue and bone allograft implants. CTS will initially begin to convert their soft tissue operations to the CLEARANT PROCESS and then migrate the technology to their hard-tissue processing. Under the CSS agreement, CTS can outsource the irradiation of hard and soft tissue allografts to Clearant. Clearant will then process the allografts utilizing their proprietary technology. This outsourcing allows CTS to better utilize internal resources as well as benefit from economies of scale that Clearant can achieve.

"We are very pleased to be able to offer the CLEARANT PROCESS to our clients," said Dr. Judith Woll, Chief Executive Officer of Community Blood Center/Community Tissue Services. "Our clients and their patients deserve the safest implants possible, and with our adoption of the CLEARANT PROCESS, they now have access to this exciting new technology. And with the convenience of the Clearant Sterilization Service, our decision became quite simple."

"Community Tissue Services is a significant addition to our growing list of licensees," said Alain Delongchamp, Chief Executive Officer of Clearant, Inc. "CTS's adoption of the Clearant Sterilization Service reinforces the strength of this new service and the convenience that it offers our tissue banking partners. We look forward to working closely with CTS in the future."

Clearant currently has nine devitalized human tissue bank customers under contract with the addition of this contact. This CTS agreement increases the number of Clearant Sterilization Service contracts to four.

About Clearant, Inc.

Clearant, Inc., a biotechnology company headquartered in Los Angeles, California, is a leader in pathogen inactivation for biological products. Clearant, Inc. has developed the patent-protected CLEARANT PROCESS(R), designed to substantially reduce all types of pathogens in biological products while maintaining a high degree of the underlying protein. Various sterilization methods on the market today only kill specific types of pathogens, such as bacteria or lipid-enveloped viruses, for specific products. The CLEARANT PROCESS(R) can substantially reduce all types of pathogens for products across many market segments including plasma proteins, tissue implants, recombinant products and blood products, and can be applied at various stages of product processing/manufacturing, including in the final container.

About Community Tissue Services

Community Tissue Services (CTS), a not-for-profit tissue bank, was founded in Dayton, Ohio in 1986 as a division of the Community Blood Center. The tissue bank was established to help patients in need of life saving or life enhancing tissue grafts. CTS serves the public through recovery, processing and distribution of human tissue grafts used for transplantation and is an accredited member of the American Association of Tissue Banks.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC.

For more information about Clearant, Inc., please see www.clearant.com.